Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 10Myelodysplastic Syndromes 3Lymphoma, Non-Hodgkin 3Leukemia 3Multiple Myeloma 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Hodgkin Disease 2Gliosarcoma 2Glioblastoma 2Warts 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pinealoma 1Neutropenia 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Medulloblastoma 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma 1Leukopenia 1Leukemia, Lymphocytic, Chronic, B-Cell 1Infections 1Immunologic Deficiency Syndromes 1Hematologic Neoplasms 1Graft vs Host Disease 1Glioma 1Brain Neoplasms 1Agammaglobulinemia 1Acquired Immunodeficiency Syndrome 1

Interventions

plerixafor 1ammonium trichloro(dioxoethylene-O,O'-)tellurate 1Human Papillomavirus Recombinant Vaccine nonavalent 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Warts × plerixafor × Clear all
NCT00967785 2026-05-22

A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
20 enrolled

Agammaglobulinemia, Immunologic Deficiency Syndromes, Infections, Leukopenia, Neutropenia, Warts

Data powered by HemOnc (CC BY 4.0) Colophon âš¡